Announcements
- Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
- Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
More ▼
Key statistics
As of last trade, Sagimet Biosciences Inc (0O2:STU) traded at 4.32, 111.76% above the 52 week low of 2.04 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.20 |
---|---|
High | 4.32 |
Low | 4.18 |
Bid | 4.32 |
Offer | 4.40 |
Previous close | 4.26 |
Average volume | 0.00 |
---|---|
Shares outstanding | 31.91m |
Free float | 26.05m |
P/E (TTM) | -- |
Market cap | 148.08m USD |
EPS (TTM) | -1.23 USD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼